Navigation Links
New Interim Analysis From Observational Study Suggests That Delivery Of Insulin Via Valeritas' V-Go Shows Promise In Improving Glycemic Control For Patients With Type 2 Diabetes
Date:5/2/2013

p>1

The primary objective of the observational study was to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the categories of baseline treatment. Patients in the study were followed on their current therapy for up to 6 weeks before starting the V-Go insulin delivery device. The study, observational in nature, has no mandated or forced titration instructions to guide insulin therapy with the exception of starting doses for V-Go basal rate options.1

The interim analysis of the observational study suggests that 47 patients had continuous V-Go use for a minimum of 3 months. Most of the patients in the study were men with an average age of 60 having diabetes for 13 years. At the time of this interim analysis, A1C levels for the study participants reduced from 9.0 percent to 8.6 percent during the 4 to 6 week run-in phase. After the run-in period and starting the V-Go, the interim results suggest that patient A1C levels further improved with a mean change from 8.6 percent to 7.8 percent; P<0.0001 from month 0 to month 3. Five patients reported adverse events probably related to V-Go (primarily rash or skin irritation). Six patients reported hypoglycemia <70 mg/dL. There was no significant change in weight. Additionally, total daily insulin dose was reduced by 19 percent (12.5 units) on average.1

About Diabetes

In order to fuel the human body's cells with glucose, or sugar, insulin is required. While the body continuously produces insulin, people with Type 2 diabetes, the most common form of diabetes, either do not produce enough insulin, or their bodies cannot use the insulin adequately. When there is not enough, or insulin is not used properly, glucose builds up in the blood instead of going into the body's cells. If not controlled properly, diabetes can increase the risk of heart disease, blindness, amputati
'/>"/>

SOURCE Valeritas, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
2. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
3. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
4. Psyadon Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
5. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
6. Sihuan Pharmaceutical Announces 2012 Interim Results
7. Medical Marijuana Inc. Announces Ted Caligiuri as Interim President and CEO
8. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
9. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
10. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
11. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Eisai ... announced today that an article based on post-hoc analyses from ... Weight Loss While on Lorcaserin, Diet, and Exercise as a ... the online issue of Obesity , the official peer ... analyses was to identify whether there is an early treatment ...
(Date:7/30/2014)... 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), ... its expertise in opioid antagonists, announced today that ... prominent international research and development foundation. ... research-based initiatives, including those addressing health issues. Lightlake ... delivery of naloxone that could widely expand its ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... April 29 Wellcore Corporation, a Silicon Valley-based ... safety, begins shipping its highly anticipated Wellcore system today. ... live more active, independent lives, the Wellcore system offers ... will work outside of the home, unlike other fall ...
... on pharma industry , , , ... two whistleblower lawsuits that is being settled as part of Ortho-McNeil-Janssen Pharmaceuticals Inc.,s and Ortho-McNeil Pharmaceutical LLC,s ... northern Virginia . , , , ... , , ...
Cached Medicine Technology:The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available 2The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available 3Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 2Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 3Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax 4
(Date:7/30/2014)... news of an Ohio teen who died of a ... the normally well-tolerated and mass-consumed substance. To help prevent ... much caffeine, scientists are reporting progress toward a rapid, ... stimulant in most beverages and even breast milk. Their ... Food Chemistry . , Mani Subramanian and colleagues note ...
(Date:7/30/2014)... Los Angeles, CA (PRWEB) July 30, 2014 ... Ghasri, now offers comprehensive cosmetic dental treatments that can ... office, Sunset Plaza Dental. Healthy teeth and gums form ... affect a person’s smile. While minor chips, misshapen teeth ... can all detract from a smile’s appearance. The right ...
(Date:7/30/2014)... 2014 All the children at Father’s ... rejection, abuse and exploitation tend to mar their respective ... and dejection. Quality youth development has underpinnings in a ... boosts confidence and in the foreseeable future, would assist ... light that the mere presence of Foundation members in ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- ,Middle-aged adults ... twice as likely as others to develop severe memory ... The British researchers said their findings could help ... might benefit from help for problem drinking. "We ... and levels of current alcohol consumption -- that understanding ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 We know pregnancy ... to peanut butter and ice cream—but the latest episode of ... MDs , just posted online, has a recipe that is ... a James Beard Award-winning chef serves up an easy recipe ... is the executive chef at Rasika, which was named one ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 3Health News:The Edusei Foundation Donates Food and Assorted Items to the Fathers’ Home Care Ministries in Takoradi, Ghana 2Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2Health News:What to Eat When You’re Expecting 2
... Duke University Medical Center researchers, African-Americans have a notably ... hepatitis C than non-Hispanic whites. ,The ... which is the journal for the members of the ... with hepatitis C (HCV) infections experience a reduced response ...
... A new study published in the Journal of Neurology, Neurosurgery ... during //two peak periods. Japanese researchers who conducted the study ... and 8am and 6pm and 8pm. ,The researchers examined ... was lowest during sleep. This may probably be due to ...
... Health Service Executive in Ireland is all set to offer ... overcrowding.// ,The Irish Examiner reports that hospitals may be ... the A&E crisis, where patients are made to wait for ... patients are not made to wait over 24 hours. Also ...
... University of Siena, researchers found that cartoons are twice as ... medical procedures, such as having a blood sample taken. ... Scatte Clinic divided 69 children, aged between 7 and 12, ... kids started watching TV cartoons at least two minutes before ...
... a little extra income can make a big difference in helping ... the upper end," said Meredith Minkler, an author of a report ... England Journal of Medicine. "We always knew there was a major ... that the middle class was at a substantial disadvantage to slightly ...
... west of Scotland; Inverclyde, is to be revamped.// ... and increase in the range of community-based services will ... ,An already existing ward at Inverclyde Royal Hospital ... Children's hospital services, therapy services currently provided by ...
Cached Medicine News:Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 2Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 3Health News:The higher the income the lower the disability rates! 2Health News:A new deal for childcare services given go-ahead 2
... is a primary component of an integrated ... sampling, and slide preparation all strictly ... LBP Processor produces high-quality sample slides featuring ... of cytology specimen types. It processes 40 ...
... offer a safe alternative to using positive ... applications such as PCR(a), pipetting radioactive materials ... are excellent for tissue culture, gel loading, ... prevent aerosol contaminants and liquids from reaching ...
... Packed conveniently in plastic-wrapped racks of ... to useno need to autoclave. Sterilized Diamond ... efficient sterilization and are delivered with a ... irradiation. Sterilized Diamond Tips are certified free ...
... been designed to optimize the accuracy and ... tip products is widely recognized by customers ... been extended over the years and now ... special tips including filter tips, certified pure ...
Medicine Products: